{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:50:53Z","timestamp":1773294653460,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1097\/chi.0b013e3180335ad1","type":"journal-article","created":{"date-parts":[[2007,4,17]],"date-time":"2007-04-17T08:02:15Z","timestamp":1176796935000},"page":"566-572","source":"Crossref","is-referenced-by-count":29,"title":["Effect of Two Different Methods of Initiating Atomoxetine on the Adverse Event Profile of Atomoxetine"],"prefix":"10.1016","volume":"46","author":[{"given":"LAURENCE L.","family":"GREENHILL","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JEFFREY H.","family":"NEWCORN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAITAO","family":"GAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PETER D.","family":"FELDMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/chi.0b013e3180335ad1_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0924-977X(02)00012-3","article-title":"Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen","volume":"12","author":"Bogetto","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1097\/chi.0b013e3180335ad1_bib2","series-title":"ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations","author":"DuPaul","year":"1998"},{"key":"10.1097\/chi.0b013e3180335ad1_bib3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4088\/JCP.v61n1203","article-title":"Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone","volume":"61","author":"Feifel","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1097\/chi.0b013e3180335ad1_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0376-8716(02)00053-4","article-title":"Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users","volume":"67","author":"Heil","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1097\/chi.0b013e3180335ad1_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4088\/JCP.v60n1202","article-title":"Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients","volume":"60","author":"Hirschfeld","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1097\/chi.0b013e3180335ad1_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/j.1552-4604.1994.tb03977.x","article-title":"Analysis of adverse events in a dose titration study","volume":"34","author":"Hsu","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1097\/chi.0b013e3180335ad1_bib7","series-title":"Kiddie-SADS-Present and Lifetime Version (K-SADS-PL)","author":"Kaufman","year":"1996"},{"key":"10.1097\/chi.0b013e3180335ad1_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.114.1.e1","article-title":"Once-daily atomoxetine treatment for children with attention-deficit\/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial","volume":"114","author":"Kelsey","year":"2004","journal-title":"Pediatrics"},{"key":"10.1097\/chi.0b013e3180335ad1_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/00003088-199937060-00002","article-title":"Pharmacokinetics and clinical effectiveness of methylphenidate","volume":"37","author":"Kimko","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1097\/chi.0b013e3180335ad1_bib10","unstructured":"Kratochvil CJ, Wernicke J, Schuh K, Zhang S, Faries D, Kelsey D (2002), Long-term safety of atomoxetine in children treated for ADHD. Scientific Proceedings of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, May"},{"key":"10.1097\/chi.0b013e3180335ad1_bib11","series-title":"Antiepileptic Drug Development","first-page":"231","article-title":"Cognitive and behavioral assessments in antiepileptic drug trials.","author":"Meador","year":"1998"},{"key":"10.1097\/chi.0b013e3180335ad1_bib12","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","article-title":"Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study","volume":"159","author":"Michelson","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1097\/chi.0b013e3180335ad1_bib13","series-title":"Physician's Desk Reference","author":"Physician's Desk Reference","year":"2005"},{"key":"10.1097\/chi.0b013e3180335ad1_bib14","series-title":"SAS\/STAT Software: Changes and Enhancements Through Release 6.12","author":"SAS Institute","year":"1997"},{"key":"10.1097\/chi.0b013e3180335ad1_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4088\/JCP.v63n1209","article-title":"Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit\/hyperactivity disorder","volume":"63","author":"Spencer","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1097\/chi.0b013e3180335ad1_bib16","first-page":"811","article-title":"A bridging study of fananserin in schizophrenic patients","volume":"34","author":"Sramek","year":"1998","journal-title":"Psychopharmacol Bull"},{"key":"10.1097\/chi.0b013e3180335ad1_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/070674379403900409","article-title":"Clozapine and seizures: a review","volume":"39","author":"Toth","year":"1994","journal-title":"Can J Psychiatry"},{"key":"10.1097\/chi.0b013e3180335ad1_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1517\/14656566.6.6.1003","article-title":"Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD","volume":"6","author":"Weisler","year":"2005","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709617159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709617159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T10:19:50Z","timestamp":1568369990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856709617159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0890856709617159"],"URL":"https:\/\/doi.org\/10.1097\/chi.0b013e3180335ad1","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}